New hope for kids with AML: gentler chemo combos under trial

NCT ID NCT07059975

Recruiting now Disease control Sponsor: Joanna Yi Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-phase trial is testing two new chemotherapy combinations for children and young adults with acute myeloid leukemia (AML) who are at intermediate or high risk of relapse. The goal is to see if these combinations are tolerable and can achieve similar or better survival with fewer long-term side effects. About 36 participants will receive the new drug combinations and be followed for up to three years.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Idarubicin, fludarabine, cytarabine, venetoclax, etoposide
What this could lead to: If successful, this could lead to a more tolerable chemotherapy regimen for children with AML, potentially reducing long-term side effects while maintaining or improving survival.
What could go wrong: This is a very early, small pilot trial with only 36 participants, so results may not apply to all patients. The new combinations could still cause serious side effects or fail to control the leukemia.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ACUTE MYELOID LEUKEMIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

acute myeloid leukemia childhood acute myeloid leukemia myeloid sarcoma Neoplasm, Residual

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ACUTE MYELOID LEUKEMIA PEDIATRIC AML

Contacts and locations

Locations

Texas Children's Cancer and Hematology Center
RECRUITING

Houston, Texas, 77030, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.